Communiqués Hemostemix Inc.

Actions

HEM

CA4236943060

Recherche biotechnologique et médicale

Marché Fermé - Toronto S.E. 15:47:18 18/08/2026			Varia. 5j.	Varia. 1 janv.
0,0750 ^CAD	0,00%		+15,38%	-16,67%

31/07	Hemostemix lève 322 250 $ CA lors de la deuxième tranche de son placement privé	MT
08/07	Hemostemix dépose une demande de commercialisation pour le traitement de la démence vasculaire, de l'angine de poitrine réfractaire et de la douleur	MT

Communiqués

12/08	Hemostemix : Dr. Ernst von Schwarz named PI of Hemostemix Longevity Clinical Trial	PU
12/08	Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial	NE
28/07	Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results	NE
22/07	Hemostemix : grants 6,280,000 options	PU
22/07	Hemostemix Grants Stock Options	NE
08/07	Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain	NE
26/06	Hemostemix Closes $360,000 First Tranche of Private Placement	NE
17/06	Hemostemix : rsquo; $1,000,000 Private Placement and Update	PU
17/06	Hemostemix' $1,000,000 Private Placement and Update	NE
26/05	Dr. Desiree Cox Appointed to Hemostemix Board of Directors	AQ
25/05	Hemostemix : Dr. Desirée Cox Appointed to Hemostemix’ Board of Directors	PU
21/05	Hemostemix : $1,000,000 Private Placement	PU
21/04	Dr. Ernst von Schwarz to Host Webinar: VesCell for Advanced Cardiac Conditions	PU
19/03	HEMOSTEMIX : CLOSES $303,967 PRIVATE PLACEMENT AT $0.12 PER SHARE	PU
09/03	Hemostemix Leadership Attending Abundance360 Summit	NE
03/02	Hemostemix : Appoints Renowned Vascular Surgeon and Principal Investigator, Dr.York Hsiang, to Advance First Nations–Led Healthcare Partnerships	PU
03/02	Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships	NE
16/01	Hemostemix Receives FDA Support for Its Basket Protocol Approach	NE
31/12	Hemostemix Closes $480,000 Private Placement at $0.12 per Share	NE
23/12	Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01	NE
18/12	Hemostemix : Granted Trademark 'KNOW YOUR HEALTH' in Japan.	PU
18/12	Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI	PU
18/12	Hemostemix : to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida	PU
18/12	Hemostemix : Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia	PU
18/12	Hemostemix : Featured at Innovations in Wound Healing 2025, Key West, December 11-14	PU